- Home
- ZWS vs NUVL Comparison
ZWS vs NUVL Comparison
Compare ZWS & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZWS
- NUVL
- Stock Information
- Founded
- ZWS 1891
- NUVL 2017
- Country
- ZWS United States
- NUVL United States
- Employees
- ZWS N/A
- NUVL N/A
- Industry
- ZWS Industrial Machinery/Components
- NUVL Biotechnology: Pharmaceutical Preparations
- Sector
- ZWS Industrials
- NUVL Health Care
- Exchange
- ZWS Nasdaq
- NUVL Nasdaq
- Market Cap
- ZWS 5.9B
- NUVL 5.4B
- IPO Year
- ZWS 2012
- NUVL 2021
- Fundamental
- Price
- ZWS $37.56
- NUVL $80.48
- Analyst Decision
- ZWS Buy
- NUVL Strong Buy
- Analyst Count
- ZWS 6
- NUVL 10
- Target Price
- ZWS $37.67
- NUVL $119.60
- AVG Volume (30 Days)
- ZWS 736.6K
- NUVL 582.7K
- Earning Date
- ZWS 07-29-2025
- NUVL 08-07-2025
- Dividend Yield
- ZWS 0.96%
- NUVL N/A
- EPS Growth
- ZWS 40.41
- NUVL N/A
- EPS
- ZWS 0.98
- NUVL N/A
- Revenue
- ZWS $1,581,500,000.00
- NUVL N/A
- Revenue This Year
- ZWS $4.31
- NUVL N/A
- Revenue Next Year
- ZWS $4.71
- NUVL N/A
- P/E Ratio
- ZWS $39.11
- NUVL N/A
- Revenue Growth
- ZWS 3.22
- NUVL N/A
- 52 Week Low
- ZWS $27.74
- NUVL $55.54
- 52 Week High
- ZWS $41.15
- NUVL $113.51
- Technical
- Relative Strength Index (RSI)
- ZWS 64.57
- NUVL 59.85
- Support Level
- ZWS $36.28
- NUVL $76.27
- Resistance Level
- ZWS $37.82
- NUVL $80.90
- Average True Range (ATR)
- ZWS 0.66
- NUVL 2.55
- MACD
- ZWS 0.14
- NUVL 0.19
- Stochastic Oscillator
- ZWS 88.34
- NUVL 81.61
About ZWS Zurn Elkay Water Solutions Corporation
Zurn Elkay Water Solutions Corp designs procures, manufactures, and markets a range of clean water solutions for drinking water, hygiene, and sustainable water management. The company's product portfolio includes professional-grade water control and safety, water distribution and drainage, drinking water, finish plumbing, hygienic, environmental and site works products for public and private spaces.
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.